5'-N-ethylcarboxamidoinosine

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: 5'-N-ethylcarboxamidoinosine
• 英文别名: (2S,3S,4R,5R)-N-ethyl-3,4-dihydroxy-5-(6-oxo-1,6-dihydro-9H-purin-9-yl)tetrahydrofuran-2-carboxamide；(2S,3S,4R,5R)-N-ethyl-3,4-dihydroxy-5-(6-oxo-1H-purin-9-yl)oxolane-2-carboxamide
• 化学式: C₁₂H₁₅N₅O₅
• 分子量: 309.282
• InChiKey: ZSGAHCIPJXWFOB-FLNNQWSLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.8
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  138
• 氢给体数：
  4
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  5'-N-ethylcarboxamidoinosine 在 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 生成 (2S,3S,4R,5R)-5-[6-[6-[[4-[5-amino-4-benzoyl-3-[3-(trifluoromethyl)phenyl]thiophen-2-yl]benzoyl]amino]hexylamino]purin-9-yl]-N-ethyl-3,4-dihydroxyoxolane-2-carboxamide
  参考文献：
  名称：

  N-取代的N 6取代腺苷衍生物作为偏腺苷A 1受体激动剂的构效关系研究。

  摘要：

  腺苷A 1受体（A 1 AR）是心肌缺血再灌注损伤的潜在新型治疗靶标。但是，迄今为止，由于剂量限制的不良反应，原型A 1 AR激动剂的临床翻译受到了阻碍。最近，我们证明，由连接至变构部分的腺苷药效基团组成的偏向性双位激动剂1可以在不存在心动过缓的情况下刺激心脏保护性A 1 AR信号传导。因此，本研究旨在研究化合物1激动剂的构效关系。一系列的新的衍生物的1合成并进行药理学分析。对正构腺苷药效团，接头和变构2-氨基-3-苯甲酰基噻吩药效团进行了修饰，以探究其结构-活性关系，特别是在信号偏向方面以及A 1 AR活性和亚型选择性方面。总的来说，我们的发现表明，变构部分，特别是噻吩支架的4-（三氟甲基）苯基取代基，在赋予A 1 AR上的双位配体偏倚方面很重要。

  DOI：

  10.1021/acs.jmedchem.8b00047
• 作为产物：
  描述：

  2',3'-O-异丙叉肌苷 在 盐酸 、 氯化亚砜 、 2,2,6,6-四甲基哌啶氧化物 、 碘苯二乙酸 作用下， 以 甲醇 、 水 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 生成 5'-N-ethylcarboxamidoinosine
  参考文献：
  名称：

  N-取代的N 6取代腺苷衍生物作为偏腺苷A 1受体激动剂的构效关系研究。

  摘要：

  腺苷A 1受体（A 1 AR）是心肌缺血再灌注损伤的潜在新型治疗靶标。但是，迄今为止，由于剂量限制的不良反应，原型A 1 AR激动剂的临床翻译受到了阻碍。最近，我们证明，由连接至变构部分的腺苷药效基团组成的偏向性双位激动剂1可以在不存在心动过缓的情况下刺激心脏保护性A 1 AR信号传导。因此，本研究旨在研究化合物1激动剂的构效关系。一系列的新的衍生物的1合成并进行药理学分析。对正构腺苷药效团，接头和变构2-氨基-3-苯甲酰基噻吩药效团进行了修饰，以探究其结构-活性关系，特别是在信号偏向方面以及A 1 AR活性和亚型选择性方面。总的来说，我们的发现表明，变构部分，特别是噻吩支架的4-（三氟甲基）苯基取代基，在赋予A 1 AR上的双位配体偏倚方面很重要。

  DOI：

  10.1021/acs.jmedchem.8b00047

文献信息

• Structure-Activity Relationships of N6-Benzyladenosine-5'-uronamides as A3-Selective Adenosine Agonists
  作者：Carola Gallo-Rodriguez、Xiao-duo Ji、Neli Melman、Barry D. Siegman、Lawrence H. Sanders、Jeraldine Orlina、Bilha Fischer、Quanlong Pu、Mark E. Olah

  DOI：10.1021/jm00031a014

  日期：1994.3

  Adenosine analogues modified at the 5'-position as uronamides and/or as N-6-benzyl derivatives were synthesized. These derivatives were examined for affinity in radioligand binding assays at the newly discovered rat brain A(3) adenosine receptor and at rat brain A(1) and Az, receptors. 5'Uronamide substituents favored AS selectivity in the order N-methyl > N-ethyl approximate to unsubstituted carboxamide > N-cyclopropyl. 5'-(N-Methylcarboxamido)-N-6-benzyladenosine was 37-56-fold more selective for Ag receptors. Potency at A(3) receptors was enhanced upon substitution of the benzyl substituent with nitro and other groups. 5'-N-Methyluronamides and N-6-(3-substituted-benzyl) adenosines are optimal for potency and selectivity at A(3) receptors. A series of 3-(halobenzyl)5'-N-ethyluronamide derivatives showed the order of potency at A(1) and A(2)a receptors of I similar to Br > Cl > F. At A(3) receptors the 3-F derivative was weaker than the other halo derivatives. 5'-N-Methyl-N-6- (3-iodobenzyl) adenosine displayed a K-i value of 1.1 nM at A(3) receptors and selectivity versus A(1) and A(2a), receptors of 50-fold. A series of methoxybenzyl derivatives showed that a C-methoxy group best favored A(3) selectivity. A 4-sulfobenzyl derivative was a specific ligand at A(3) receptors of moderate potency. An aryl amino derivative was prepared as a probe for radioiodination and receptor cross-linking.
• Deamination of 6-Aminodeoxyfutalosine in Menaquinone Biosynthesis by Distantly Related Enzymes
  作者：Alissa M. Goble、Rafael Toro、Xu Li、Argentina Ornelas、Hao Fan、Subramaniam Eswaramoorthy、Yury Patskovsky、Brandan Hillerich、Ron Seidel、Andrej Sali、Brian K. Shoichet、Steven C. Almo、Subramanyam Swaminathan、Martin E. Tanner、Frank M. Raushel

  DOI：10.1021/bi400750a

  日期：2013.9.17

  Proteins of unknown function belonging to cog1816 and cog0402 were characterized. Sav2595 from Steptomyces avermitilis MA-4680, Ace10264 from Acidothermus cellulolyticus 11B, Nis0429 from Nitratiruptor sp. SB155-2 and Dr0824 from Deinococcus radiodurans R1 were cloned, purified, and their substrate profiles determined. These enzymes were previously incorrectly annotated as adenosine deaminases or chlorohydrolases. It was shown here that these enzymes actually deaminate 6-aminodeoxyfutalosine. The deamination of 6-aminodeoxyfutalosine is part of an alternative menaquinone biosynthetic pathway that involves the formation of futalosine. 6-Aminodeoxyfutalosine is deaminated by these enzymes with catalytic efficiencies greater than 106 M-1 s(-1), Km values of 0.9-6.0 mu M, and k(cat) values of 1.2-8.6 Adenosine, 2'-deoxyadenosine, thiomethyladenosine, and S-adenosylhomocysteine are deaminated at least an order of magnitude slower than 6-aminodeoxyfutalosine. The crystal structure of Nis0429 was determined and the substrate, 6-aminodeoxyfutalosine, was positioned in the active site on the basis of the presence of adventitiously bound benzoic acid. In this model, Ser-145 interacts with the carboxylate moiety of the substrate. The structure of.Dr0824 was also determined, but a collapsed active site pocket prevented docking of substrates. A computational model of Sav2595 was built on the basis of the crystal structure of adenosine deaminase and substrates were docked. The model predicted a conserved arginine after beta-strand 1 to be partially responsible for the substrate specificity of Sav2595.
• A Structure–Activity Relationship Study of Bitopic <i>N</i>⁶-Substituted Adenosine Derivatives as Biased Adenosine A₁ Receptor Agonists
  作者：Luigi Aurelio、Jo-Anne Baltos、Leigh Ford、Anh T. N. Nguyen、Manuela Jörg、Shane M. Devine、Celine Valant、Paul J. White、Arthur Christopoulos、Lauren T. May、Peter J. Scammells

  DOI：10.1021/acs.jmedchem.8b00047

  日期：2018.3.8

  prototypical A1AR agonists has been hindered due to dose limiting adverse effects. Recently, we demonstrated that the biased bitopic agonist 1, consisting of an adenosine pharmacophore linked to an allosteric moiety, could stimulate cardioprotective A1AR signaling in the absence of unwanted bradycardia. Therefore, this study aimed to investigate the structure–activity relationship of compound 1 biased

  腺苷A 1受体（A 1 AR）是心肌缺血再灌注损伤的潜在新型治疗靶标。但是，迄今为止，由于剂量限制的不良反应，原型A 1 AR激动剂的临床翻译受到了阻碍。最近，我们证明，由连接至变构部分的腺苷药效基团组成的偏向性双位激动剂1可以在不存在心动过缓的情况下刺激心脏保护性A 1 AR信号传导。因此，本研究旨在研究化合物1激动剂的构效关系。一系列的新的衍生物的1合成并进行药理学分析。对正构腺苷药效团，接头和变构2-氨基-3-苯甲酰基噻吩药效团进行了修饰，以探究其结构-活性关系，特别是在信号偏向方面以及A 1 AR活性和亚型选择性方面。总的来说，我们的发现表明，变构部分，特别是噻吩支架的4-（三氟甲基）苯基取代基，在赋予A 1 AR上的双位配体偏倚方面很重要。